CHARLES RIVER LABORATORIES (CRL) Stock Fundamental Analysis
USA - NYSE:CRL - US1598641074 - Common Stock
168.05 USD
-2.83 (-1.66%)
168.05 USD
0 (0%)
Taking everything into account, CRL scores 4 out of 10 in our fundamental rating. CRL was compared to 58 industry peers in the Life Sciences Tools & Services industry. CRL has an average financial health and profitability rating. CRL is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CRL was profitable.
CRL had a positive operating cash flow in the past year.
In the past 5 years CRL has always been profitable.
Each year in the past 5 years CRL had a positive operating cash flow.
1.2 Ratios
CRL's Return On Assets of -0.92% is fine compared to the rest of the industry. CRL outperforms 60.34% of its industry peers.
The Return On Equity of CRL (-2.06%) is comparable to the rest of the industry.
CRL has a better Return On Invested Capital (5.72%) than 74.14% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CRL is significantly below the industry average of 13.50%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.92% | ||
| ROE | -2.06% | ||
| ROIC | 5.72% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
1.3 Margins
In the last couple of years the Profit Margin of CRL has declined.
Looking at the Operating Margin, with a value of 11.64%, CRL is in the better half of the industry, outperforming 72.41% of the companies in the same industry.
In the last couple of years the Operating Margin of CRL has remained more or less at the same level.
With a Gross Margin value of 35.03%, CRL is not doing good in the industry: 62.07% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.64% | ||
| PM (TTM) | N/A | ||
| GM | 35.03% |
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CRL is destroying value.
CRL has less shares outstanding than it did 1 year ago.
The number of shares outstanding for CRL has been increased compared to 5 years ago.
CRL has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.35 indicates that CRL is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of CRL (2.35) is better than 62.07% of its industry peers.
The Debt to FCF ratio of CRL is 4.04, which is a neutral value as it means it would take CRL, 4.04 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 4.04, CRL is doing good in the industry, outperforming 70.69% of the companies in the same industry.
CRL has a Debt/Equity ratio of 0.70. This is a neutral value indicating CRL is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.70, CRL is doing worse than 72.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 4.04 | ||
| Altman-Z | 2.35 |
ROIC/WACC0.56
WACC10.16%
2.3 Liquidity
A Current Ratio of 1.36 indicates that CRL should not have too much problems paying its short term obligations.
CRL has a worse Current ratio (1.36) than 79.31% of its industry peers.
CRL has a Quick Ratio of 1.10. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of CRL (1.10) is worse than 74.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.1 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.25% over the past year.
The Earnings Per Share has been growing by 8.93% on average over the past years. This is quite good.
Looking at the last year, CRL shows a decrease in Revenue. The Revenue has decreased by -1.92% in the last year.
Measured over the past years, CRL shows a quite strong growth in Revenue. The Revenue has been growing by 9.09% on average per year.
EPS 1Y (TTM)4.25%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%-6.18%
Revenue 1Y (TTM)-1.92%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%-0.49%
3.2 Future
CRL is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.43% yearly.
CRL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.43% yearly.
EPS Next Y-0.31%
EPS Next 2Y2.66%
EPS Next 3Y4.71%
EPS Next 5Y6.43%
Revenue Next Year-0.98%
Revenue Next 2Y0.71%
Revenue Next 3Y2.16%
Revenue Next 5Y2.43%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 15.93 indicates a correct valuation of CRL.
Compared to the rest of the industry, the Price/Earnings ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 93.10% of the companies listed in the same industry.
CRL is valuated rather cheaply when we compare the Price/Earnings ratio to 25.67, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 15.45, which indicates a correct valuation of CRL.
Based on the Price/Forward Earnings ratio, CRL is valued cheaper than 93.10% of the companies in the same industry.
CRL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 31.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.93 | ||
| Fwd PE | 15.45 |
4.2 Price Multiples
CRL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CRL is cheaper than 96.55% of the companies in the same industry.
CRL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CRL is cheaper than 93.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.3 | ||
| EV/EBITDA | 11.74 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)1.78
EPS Next 2Y2.66%
EPS Next 3Y4.71%
5. Dividend
5.1 Amount
No dividends for CRL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
168.05
-2.83 (-1.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners105.46%
Inst Owner Change-2.2%
Ins Owners0.88%
Ins Owner Change6.15%
Market Cap8.27B
Revenue(TTM)4.05B
Net Income(TTM)-69.22M
Analysts72.17
Price Target192.74 (14.69%)
Short Float %4.3%
Short Ratio2.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.56%
Min EPS beat(2)11.44%
Max EPS beat(2)23.68%
EPS beat(4)4
Avg EPS beat(4)11.21%
Min EPS beat(4)4.03%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)10.55%
EPS beat(12)12
Avg EPS beat(12)8.62%
EPS beat(16)16
Avg EPS beat(16)6.82%
Revenue beat(2)2
Avg Revenue beat(2)3.59%
Min Revenue beat(2)3.45%
Max Revenue beat(2)3.74%
Revenue beat(4)4
Avg Revenue beat(4)2.63%
Min Revenue beat(4)0.91%
Max Revenue beat(4)3.74%
Revenue beat(8)7
Avg Revenue beat(8)1.68%
Revenue beat(12)10
Avg Revenue beat(12)1.88%
Revenue beat(16)11
Avg Revenue beat(16)1.12%
PT rev (1m)5.84%
PT rev (3m)20.01%
EPS NQ rev (1m)-0.35%
EPS NQ rev (3m)-1.61%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)6.11%
Revenue NQ rev (1m)0.38%
Revenue NQ rev (3m)3.17%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)2.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.93 | ||
| Fwd PE | 15.45 | ||
| P/S | 2.05 | ||
| P/FCF | 14.3 | ||
| P/OCF | 10.5 | ||
| P/B | 2.47 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.74 |
EPS(TTM)10.55
EY6.28%
EPS(NY)10.88
Fwd EY6.47%
FCF(TTM)11.76
FCFY7%
OCF(TTM)16
OCFY9.52%
SpS81.87
BVpS68.14
TBVpS-3.77
PEG (NY)N/A
PEG (5Y)1.78
Graham Number127.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.92% | ||
| ROE | -2.06% | ||
| ROCE | 7.24% | ||
| ROIC | 5.72% | ||
| ROICexc | 5.88% | ||
| ROICexgc | 13.43% | ||
| OM | 11.64% | ||
| PM (TTM) | N/A | ||
| GM | 35.03% | ||
| FCFM | 14.36% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
ROICexc(3y)7.59%
ROICexc(5y)7.91%
ROICexgc(3y)18.25%
ROICexgc(5y)19.94%
ROCE(3y)9.27%
ROCE(5y)9.62%
ROICexgc growth 3Y-14.69%
ROICexgc growth 5Y-4.68%
ROICexc growth 3Y-7.59%
ROICexc growth 5Y-3.19%
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
F-Score4
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 4.04 | ||
| Debt/EBITDA | 2.59 | ||
| Cap/Depr | 48.58% | ||
| Cap/Sales | 5.19% | ||
| Interest Coverage | 4.15 | ||
| Cash Conversion | 87.57% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.1 | ||
| Altman-Z | 2.35 |
F-Score4
WACC10.16%
ROIC/WACC0.56
Cap/Depr(3y)90.89%
Cap/Depr(5y)85.95%
Cap/Sales(3y)7.21%
Cap/Sales(5y)6.76%
Profit Quality(3y)1669.68%
Profit Quality(5y)1049.89%
High Growth Momentum
Growth
EPS 1Y (TTM)4.25%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%-6.18%
EPS Next Y-0.31%
EPS Next 2Y2.66%
EPS Next 3Y4.71%
EPS Next 5Y6.43%
Revenue 1Y (TTM)-1.92%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%-0.49%
Revenue Next Year-0.98%
Revenue Next 2Y0.71%
Revenue Next 3Y2.16%
Revenue Next 5Y2.43%
EBIT growth 1Y-25.61%
EBIT growth 3Y-4.53%
EBIT growth 5Y7.56%
EBIT Next Year34.27%
EBIT Next 3Y14.36%
EBIT Next 5Y10.95%
FCF growth 1Y99.92%
FCF growth 3Y-1.94%
FCF growth 5Y8.06%
OCF growth 1Y25.98%
OCF growth 3Y-1.16%
OCF growth 5Y8.84%
CHARLES RIVER LABORATORIES / CRL FAQ
What is the fundamental rating for CRL stock?
ChartMill assigns a fundamental rating of 4 / 10 to CRL.
Can you provide the valuation status for CHARLES RIVER LABORATORIES?
ChartMill assigns a valuation rating of 6 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.
How profitable is CHARLES RIVER LABORATORIES (CRL) stock?
CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.
What is the valuation of CHARLES RIVER LABORATORIES based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CHARLES RIVER LABORATORIES (CRL) is 15.93 and the Price/Book (PB) ratio is 2.47.
How financially healthy is CHARLES RIVER LABORATORIES?
The financial health rating of CHARLES RIVER LABORATORIES (CRL) is 4 / 10.